High levels (450%) of anxiety are reported in patients undergoing screening for prostate cancer, which may affect health-related quality of life. We aimed to determine the level and prevalence of anxiety and depression and to identify those aspects of the diagnostic pathway that induce the most stress in men being investigated for prostate cancer. A total of 159 prostate-specific antigenunscreened men undergoing a transrectal ultrasound-guided biopsy of the prostate (TRUS-B) completed two questionnaires, prior to their biopsy and before receiving results, containing the Hospital Anxiety and Depression Scale (HADS) and a 10-point Visual Analogue Scale (VAS). Median scores and prevalence of anxiety (4-5, 4-7%) and depression (1-2, 1.4%) respectively were low for both questionnaires. Waiting for biopsy results received the highest median VAS score (6) and was the most stressful event in 65% of men. There is a low incidence of clinically significant anxiety and depression in men being investigated for prostate cancer but questionnaires such as HADS identify patients with psychological distress who may benefit from early counselling. Uncertainty about the future while awaiting biopsy results after TRUS-B seems to be the most stressful event in patients' lives and minimizing this wait should help optimize patient care.
Introduction
Recently there has been much research conducted into the psychological impact of life-threatening diseases such as cancer. There is a high incidence of psychiatric disturbance reported in women who were recently diagnosed with breast cancer. 1 There have been conflicting reports however, with regard to the prevalence of mental health disturbance in men being investigated and treated for prostate cancer; with some studies reporting a high (50-64%) prevalence of anxiety, 2, 3 whereas others report low levels in men being investigated 4 or treated for early localized prostate cancer 5 that are no different from those of a matched normal population. In addition, other reports suggest that men with advanced prostate cancer had significantly greater psychological distress as compared to those with early stage disease. 6 Although men with lower urinary tract symptoms (LUTS) are not at a greater risk of prostate cancer as compared to asymptomatic men of the same age, 7 men presenting with LUTS in the United Kingdom do express anxiety about prostate cancer. 8 Various conditions inducing anxiety that relate to the measurement of prostate-specific antigen (PSA) have been described. These include PSA-itis (anxiety related to the knowledge of serum PSA) 9 and PSA-dynia (a state of emotional or physical distress due to an elevated PSA level). 10 Reports from the Rotterdam trial (a participant in the European Randomized Study of Screening for Prostate Cancer) 11 and the ProtecT (Prostate Testing for Cancer and Treatment) Study 4 however have shown no significant change in anxiety levels during PSA screening. Most men in the United Kingdom do not undergo PSA screening, but have a PSA test, either on self-request or on request by their general practitioner (GP) as part of investigations for LUTS. They may be referred to a urology department for a transrectal ultrasound-guided biopsy of the prostate (TRUS-B), with an abnormal PSA or with a palpable abnormality on digital rectal examination or both. Little work has been done investigating the psychological burden that this subgroup of the population faces while being investigated for prostate cancer.
The objectives of our study were to determine (1) the level of anxiety and depression, (2) the prevalence of clinically significant anxiety and depression and (3) those aspects of the diagnostic pathway that induce the most stress during investigation for prostate cancer. A number of validated questionnaires have been used in the assessment of psychological distress in men being investigated and treated for prostate cancer, such as the Hospital Anxiety and Depression Scale (HADS), 5, 9 Impact of Event Scale, 5 General Health Questionnaire (GHQ-30), 5 State-Trait Anxiety Inventory (STAI), 11 Visual Analogue Scale (VAS) 3, 12 and the prostate cancer-specific Memorial Anxiety Scale for Prostate Cancer. 13 We chose the HADS to fulfil the first two objectives for its simplicity and because it is well-validated in a number of cancers. We used a VAS mapped to the diagnostic pathway (JSA Green, Green Cross Medical Ltd) to determine the level of stress experienced by these men during different stages of the diagnostic process.
Patients and methods

Patients
This study was conducted in the urology department of a district general hospital between November 2003 and January 2005 on a non-PSA-screened population. The study population was referred to our department on clinical grounds, such as a high PSA detected while investigating LUTS, or with abnormal rectal examination findings. We have previously reported an increased patient satisfaction with the use of sedation during TRUS-B, 14 and therefore all men undergoing TRUS-B in our department have propofol sedation prior to their procedure. All patients referred for a TRUS-B under sedation as a day-case procedure were informed of the nature of this study and were consented to complete the questionnaire. They were assessed by a consultant anaesthetist for suitability for sedation. Intravenous propofol (1-1.5 mg kg À1 of Diprivan, AstraZeneca, UK) was administered over 1-5 min using routine noninvasive monitoring. Standard sextant biopsies were taken with the patient in left lateral decubitus position.
Questionnaires
Patients were administered two anonymized questionnaires. The first questionnaire (QA), which was administered to patients before they underwent the biopsy collected basic demographic data, including the age at biopsy, education, employment and marital status. It also contained the HADS to assess pre-biopsy anxiety and depression. The second questionnaire (QB) was administered in outpatient clinic before patients received their biopsy results. QB contained the HADS and asked patients to specify the 'most stressful event' from a list of events, starting with the patient's decision to see his GP, awaiting to see the GP, seeing the GP, awaiting to see the hospital specialist, seeing the hospital specialist in outpatient clinic, discovering that he has to undergo a prostate biopsy, awaiting to undergo the prostate biopsy, having the biopsy and ending with awaiting the results of the biopsy. Patients were then asked to grade on a VAS of 0-10 (with 0 being the least) the stress felt by them during each of the above-mentioned events. Patients were also asked to grade on the VAS, the stress that they feel 'while attending a dentist's appointment' as a comparative stress for the VAS (JSA Green, Green Cross Medical Ltd).
The HADS was first devised to detect anxiety and depression in patients attending non-psychiatric outpatient clinics by excluding somatic items. 15 It has since been validated for use in cancer patients, both in outpatient clinic, 16, 17 as well as pre-operatively. 18 It includes two subscales, one each for anxiety (HADS-A) and depression (HADS-D), with seven questions in each arranged alternating with the other. Each answer has four options with a score from 0 to 3. The subscales thus have a maximum score of 21, with a score above 11 considered significant ('caseness' threshold). 15 The VAS has similarly been used to assess anxiety in men being investigated and treated for prostate cancer. 3, 12 We therefore used these two questionnaires to assess stress in our patients, prior to their TRUS-B, and then in the outpatient clinic.
Statistics
Basic demographic data and the questionnaire data relating to the HADS and VAS scores were analysed statistically. All data were analysed for normality of distribution (Anderson-Darling test) and equality of variance (Levene test), which showed non-normal distribution but equality of variance. The data were therefore analysed using non-parametric statistical tests. Median (95% confidence interval) and the interquartile range (IQR) were obtained for continuous data. Frequencies of individuals who scored above thresholds for the HADS, as well as frequency distribution of the 'most stressful event' were also obtained. Wilcoxon signedrank test and Kruskal-Wallis test were used to analyse differences in HADS scores between visits and different age groups respectively. Mann-Whitney U-test was used to determine difference in HADS subscale scores between groups defined by demographic factors. Friedman test with post hoc Bonferroni pair-wise multiple comparison test was used to determine differences in median VAS scores for stress experienced by patients during the different steps of the diagnostic pathway.
Results
A total of 159 men undergoing 161 TRUS-B episodes consented to fill the questionnaires before and after their TRUS-B. There were 72 correctly completed HADS questionnaires for both QA and QB, 123 for the 'most stressful event' question and 153 fully completed VAS questions (regarding stress during the diagnostic pathway). Only the 72 questionnaires containing complete data were further analysed. The mean (s.d., range) age of the sample was 69 (7.96, 44-93) years; 11 (15%) had university or higher education, 19 (26%) were actively employed and 64 (89%) were either married, or living with a partner. Median (IQR) number of days between having the TRUS-B and seeing the specialist for the results of the biopsy was 16 (13) (14) (15) (16) (17) (18) (19) (20) .
Prevalence and level of anxiety and depression as determined by HADS
The HADS score data showed non-parametric distribution for the anxiety and depression subscales at both QA Psychological distress during prostate cancer investigation NS Awsare et al and QB (Po0.005 for all, Anderson-Darling test). Levene test showed equality of variance for both anxiety (P ¼ 0.66) and depression (P ¼ 0.50) subscales in the two questionnaires (QA vs QB). Table 1 shows the level and prevalence (caseness) of anxiety and depression at QA and QB. The median levels of HADS-A and HADS-D were lower at QB as compared to QA (HADS-A, P ¼ 0.030; HADS-D, P ¼ 0.30; Wilcoxon signed-rank test). Although there was a statistically significant difference in the anxiety scores between the two questionnaires (HADS-A, P ¼ 0.030, Wilcoxon signed-rank test), the median levels were well below the 'caseness' threshold of 11 (5 for QA and 4 for QB). During this diagnostic process 4-7% of men displayed significant anxiety and 1.4% displayed significant depression (that is, score above 11). Table 2 shows the median HADS scores by age. There was a non-significant trend towards a decrease in anxiety with increasing age (P ¼ 0.80 for QA and P ¼ 0.54 for QB, Kruskal-Wallis test). The median depression score was low, and remained unchanged, except for a higher score in the age decade 81-90 years, which contained only three participants. Table 3 shows subgroup analysis of HADS scores by demographic features. In general, median anxiety and depression scores were greater in single men vs those living with a partner, in unemployed vs actively employed men and in those with a higher education vs those with none or school education. However, none of these differences achieved statistical significance (Table 3 ; P40.05, Mann-Whitney U-test).
Frequency distribution of the 'most stressful event' as determined by direct questioning and the VAS Table 4 and Figure 1 show the frequency distribution of the 'most stressful event' on direct questioning. Of 72, 47 (65%) men felt that 'waiting for the biopsy results' was the most stressful event, followed by 'waiting for the biopsy appointment' (7, 10%), 'finding the need for a biopsy' (5, 7%) and actually 'undergoing the biopsy procedure' (3, 4%). Four (6%) subjects felt that none of the aspects of the diagnostic pathway were stressful. 
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The VAS scores (Figure 2) showed that 'waiting for the biopsy results' achieved the highest median (6) score. Baseline stress (dentist appointment: median score 1.6) was fairly low in this population, and comparable to the stress associated with the GP appointment (score 1.5). In general, anxiety seemed to increase along the diagnostic pathway, and peaked just before the patient received their biopsy result. The Friedman test showed that there was a significant difference (Po0.001) in the median VAS scores. Post hoc Bonferroni pair-wise comparison showed that the VAS score of 'waiting for the biopsy results' was significantly greater than that of all the other events (P-values between 0.01 and 0.001). In addition, the VAS score of the event 'waiting to see GP' was significantly lower than that of 'needing biopsy' (P ¼ 0.013) and of 'seeing GP' lower than 'needing biopsy' (P ¼ 0.004), 'waiting for biopsy' (P ¼ 0.017) and 'having biopsy' (P ¼ 0.026).
Discussion
Although 161 questionnaires were initially completed, several of them were not filled completely. This could be attributable to the fairly large numbers of items required to be filled by the respondents, who may therefore have missed a few of them. Only those questionnaires (72) that contained complete data, including the paired HADS scores, were included in the analysis to reduce inaccuracies in analysis, and thus bias.
There was a low level of psychological distress on objective testing using the HADS in this study. The HADS questionnaire did however identify a small cohort of men with psychological distress, for whom mental health support may be appropriate. The median scores of both the anxiety and depression subscales were low, with slightly lower values for the second questionnaire (QB) as compared to the first (QA). This was statistically significant only for the anxiety subscale and is of little clinical significance in view of the low level of psychopathology noted at both times. The level as well as prevalence of depression was lower than of anxiety, with the prevalence of anxiety and depression being 4-7 and 1.4% respectively, using a threshold score of 11 and above for the HADS subscales; the cut-off level first described by Zigmond and Snaith 15 for 'definite cases'. These levels and prevalence of both anxiety and depression are similar to population norms for UK men, not matched for age, 19 as well as to other reports of PSA screening 4, 11 and from men with a diagnosis of early prostate cancer. 5 However, a recent review of the validity of the HADS stated that an optimal balance between sensitivity and specificity (0.80 each) for both HADS-A and HADS-D could be achieved by using a cut-off score of 8 þ . 20 Table 1 shows that the prevalence of anxiety and depression is much higher at this level, and this is comparable to reports that also consider this threshold, 5 as well as those that use other instruments to measure psychological distress in men with prostate cancer. 6 Our cohort of men (as in most places in the United Kingdom) did not undergo PSA screening; but were referred by their GP either with an elevated PSA following patient request or investigation for LUTS or with abnormal digital rectal examination findings. We could not find any studies in literature that have looked at psychological distress in this group of men.
There was no significant difference in HADS scores on subgroup analysis by demographic features such as age, education, employment and marital status of the subjects. There were thus no other obviously identifiable demographic risk factors that could predict whether an individual was likely to find the process stressful.
Two-thirds of men, when asked by direct questioning to specify 'the most stressful event' in their diagnostic pathway felt that 'waiting for biopsy results' was the most stressful event. Only 4% of men found the actual procedure of having the biopsy stressful. This low figure Psychological distress during prostate cancer investigation NS Awsare et al probably reflects our use of propofol sedation for the procedure. We assessed comparative levels of stress in these men by asking them to mark on the VAS, the stress they felt 'while attending a dentist appointment'. The VAS scores for different aspects of the diagnostic pathway also confirm that 'waiting for biopsy results' was the most significantly stressful event, having received the highest median score. These results are in concurrence with other longitudinal studies looking at anxiety during screening for prostate cancer. In the Rotterdam PSA screening study, state anxiety levels (STAI) were highest among those who had undergone a biopsy, but had not yet received the results. 11 Gustafsson et al. 21 measured serum cortisol as a biological marker for stress at various points during the investigation of men undergoing screening for prostate cancer. They found that the highest levels were found in men who had undergone a prostate biopsy, but were not informed of the result. The provision of rapid diagnostic services following a TRUS-B would be the most efficient way to decrease patient stress. 'One-stop breast clinics' have gone a long way in streamlining the management of symptomatic breast disease, and are associated with a high level of patient satisfaction. 22 Use of fine needle aspiration cytology (FNAC) in these clinics has a shorter turnaround time as compared to needle core biopsy (NCB). However, FNAC is less sensitive than NCB and may provide inadequate samples, and is therefore not the preferred method of pre-operative diagnosis. 23 Similarly, the assessment of prostate NCB is considerably more time consuming and requires a high degree of expertise. In addition, there are limitations on the availability of resources and therefore it may be difficult to provide such facilities for prostate cancer diagnosis.
Previous studies have looked at the prevalence of psychopathology in PSA-screened men. The present study provided the opportunity to study the level of psychological distress, as well as identify those aspects of the diagnostic pathway that induce the most stress in a population of unselected non-screened men in the United Kingdom. Although we found that the level of distress is generally low, there exists a small cohort of men who may benefit from psychological counselling. Most men seemed willing and able to complete the questionnaires. Because it does appear possible to identify this subgroup of men using simple anxiety and depression questionnaires, it would seem appropriate to screen all men for psychological distress while being investigated for prostate cancer; particularly in the absence of any other predisposing factor to identify those individuals who may require more help and support during the diagnostic pathway. We realize that the provision of such counselling services takes time to organize and may create logistic problems. In addition, some patients may not benefit from it. The number of men who require such support is however not large, and it would seem worthwhile to offer help to this select group. Finally, most men reported that they found that waiting for the biopsy result was the most stressful event, and hence every effort must be made to reduce the time interval between TRUS-B and receipt of results by patients.
